H. Lundbeck AS (FRA:LDBA) 5-Year Sortino Ratio: N/A (As of Sep. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LDBA H. Lundbeck AS FRA:LDBA
77 GF Score
Price €5.92
GF Value €5.18
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is H. Lundbeck AS 5-Year Sortino Ratio?

The 5-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past five years. As of today (2026-09-11), H. Lundbeck AS's 5-Year Sortino Ratio is Not available.


H. Lundbeck AS  (FRA:LDBA) 5-Year Sortino Ratio Explanation

The 5-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past five year. It is calculated as the annualized result of the average five-year monthly excess returns divided by the standard deviation of negative returns in the five-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.


H. Lundbeck AS 5-Year Sortino Ratio Related Terms


FRA:LDBA vs ZTS, UTHR, VTRS: 5-Year Sortino Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's 5-Year Sortino Ratio, along with its competitors' market caps and 5-Year Sortino Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


H. Lundbeck AS 5-Year Sortino Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's 5-Year Sortino Ratio distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's 5-Year Sortino Ratio falls into.


FRA:LDBA
77GF Score
H. Lundbeck AS FRA:LDBA
5-Year Sortino Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

H. Lundbeck AS 5-Year Sortino Ratio Calculation

The 5-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last five year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 5-Year Sortino Ratio can be calculated by dividing the difference between the five-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past five year.

A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.

Is H. Lundbeck AS (FRA:LDBA) Overvalued in 2026?

Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be overvalued. The current stock price of €5.92 is trading 14.3% above its estimated GF Value™ of €5.18. GuruFocus considers H. Lundbeck AS to be Modestly Overvalued.

Key valuation signals for FRA:LDBA:

  • 5-Year Sortino Ratio: N/A
  • GF Value™: €5.18 vs. price of €5.92 (14.3% above fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the FRA:LDBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


H. Lundbeck AS Business Description

Address Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
77GF Score

Get the complete analysis for FRA:LDBA

5-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.92
Price
€5.18
GF Value